Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure

被引:0
|
作者
Tang, Amber B. [1 ]
Ziaeian, Boback [2 ]
Butler, Javed [3 ,4 ]
Yancy, Clyde W. [5 ]
Fonarow, Gregg C. [2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Div Cardiol, 10833 LeConte Ave, Los Angeles, CA 90095 USA
[3] Baylor Scott & White Res Inst, Dallas, TX USA
[4] Univ Mississippi, Jackson, MS USA
[5] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA
关键词
D O I
10.1001/jamacardio.2024.3023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ImportanceGuideline-directed medical therapy (GDMT) remains underutilized on a global level, with significant disparities in access to treatment worldwide. The potential global benefits of quadruple therapy on patients with heart failure with reduced ejection fraction (HFrEF) have not yet been estimated. ObjectiveTo assess the projected population-level benefit of optimal GDMT use globally among patients with HFrEF. Design, Setting, and ParticipantsEstimates for HFrEF prevalence, contraindications to GDMT, treatment rates, and the number needed to treat for all-cause mortality at 12 months were derived from previously published sources. Potential lives saved from optimal implementation of quadruple therapy among patients with HFrEF was calculated globally and a sensitivity analysis was conducted to account for uncertainty in the existing data. Main Outcomes and MeasuresAll-cause mortality. ResultsOf an estimated 28.89 million people with HFrEF worldwide, there were 8 235 063 (95% CI, 6 296 020-10 762 972) potentially eligible for but not receiving beta-blockers, 20 387 000 (95% CI, 15 867 004-26 184 996) eligible for but not receiving angiotensin receptor-neprilysin inhibitors, 12 223 700 (95% CI, 9 376 895-15 924 973) eligible for but not receiving mineralocorticoid receptor antagonists, and 21 229 170 (95% CI, 16 537 400-27 242 688) eligible for but not receiving sodium glucose cotransporter-2 inhibitors. Optimal implementation of quadruple GDMT could potentially prevent 1 188 277 (95% CI, 767 933-1 914 561) deaths over 12 months. A large proportion of deaths averted were projected in Southeast Asia, Eastern Mediterranean and Africa, and the Western Pacific regions. Conclusions and RelevanceImprovement in use of GDMT could result in substantial mortality benefits on a global scale. Significant heterogeneity also exists across regions, which warrants additional study with interventions tailored to country-level differences for optimization of GDMT worldwide.
引用
收藏
页码:1154 / 1158
页数:5
相关论文
共 50 条
  • [41] Evaluating Pharmacist Impact on Guideline-Directed Medical Therapy in Patients With Reduced Ejection Fraction Heart Failure
    Ingram, Adam
    Valent, Megan
    Dzurec, Mary Ann
    JOURNAL OF PHARMACY PRACTICE, 2021, 34 (02) : 239 - 246
  • [42] The effect of kidney function on guideline-directed medical therapy implementation and prognosis in heart failure with reduced ejection fraction
    Banfi-Bacsardi, Fanni
    Pilecky, David
    Vamos, Mate
    Majoros, Zsuzsanna
    Torok, Gabor Marton
    Borsanyi, Tunde Dora
    Dekany, Miklos
    Solymossi, Balazs
    Andreka, Peter
    Duray, Gabor Zoltan
    Kiss, Robert Gabor
    Nyolczas, Noemi
    Muk, Balazs
    CLINICAL CARDIOLOGY, 2024, 47 (02)
  • [43] Improving Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: A Review of Implementation Strategies
    Harrington, Josephine
    Rao, Vishal N.
    Leyva, Monica
    Oakes, Megan
    Mentz, Robert J.
    Bosworth, Hayden B.
    Pagidipati, Neha J.
    JOURNAL OF CARDIAC FAILURE, 2024, 30 (02) : 376 - 390
  • [44] Bridging The Gap To Optimal Dosing For Guideline-directed Medical Therapy For Patients With Heart Failure And Reduced Ejection Fraction
    Tonleu, Franck H. Azobou
    Campbell, Martin L.
    Miller, Stephanie C.
    Steele, Nathan R.
    Arrington, Ryon L.
    Chen, ZhenChao
    Fatade, Yetunde A.
    Ogunniyi, Modele O.
    CIRCULATION, 2021, 144
  • [45] Intensity of Guideline-Directed Medical Therapy for Coronary Heart Disease and Ischemic Heart Failure Outcomes
    Crosier, Rebecca
    Austin, Peter C.
    Ko, Dennis T.
    Lawler, Patrick R.
    Stukel, Therese A.
    Farkouh, Michael E.
    Wang, Xuesong
    Spertus, John A.
    Ross, Heather J.
    Lee, Douglas S.
    AMERICAN JOURNAL OF MEDICINE, 2021, 134 (05): : 672 - +
  • [46] REPLY: Optimal Guideline-Directed Medical Therapy for Patients With Stable Ischemic Heart Disease
    Pinho-Gomes, Ana-Catarina
    Azevedo, Luis
    Taggart, David P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (24) : 2862 - 2863
  • [47] A scoring evaluation for the practical introduction of guideline-directed medical therapy in heart failure patients
    Matsukawa, Ryuichi
    Okahara, Arihide
    Tokutome, Masaki
    Itonaga, Junpei
    Koga, Eiichi
    Hara, Ayano
    Kisanuki, Hiroshi
    Sada, Masashi
    Okabe, Kousuke
    Kawai, Shunsuke
    Ogawa, Kiyohiro
    Matsuura, Hirohide
    Mukai, Yasushi
    ESC HEART FAILURE, 2023, 10 (06): : 3352 - 3363
  • [48] Time to Quadruple Guideline-Directed Medical Therapy as a Key Performance Measure for Heart Failure
    Shahid, Izza
    Fonarow, Gregg C.
    Greene, Stephen J.
    JOURNAL OF CARDIAC FAILURE, 2023, 29 (05) : 730 - 733
  • [49] Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: 5 Core Principles
    Greene, Stephen J.
    Butler, Javed
    Fonarow, Gregg C.
    CIRCULATION, 2024, 150 (06) : 422 - 424
  • [50] Early Initiation of Guideline-Directed Medical Therapy for Heart Failure After Cardiac Surgery
    Schwann, Alexandra N.
    Jaffe, Leeor M.
    Givertz, Michael M.
    Wood, Katherine L.
    Engelman, Daniel T.
    ANNALS OF THORACIC SURGERY, 2024, 118 (04): : 792 - 800